Real-world comparative safety and efficacy of tenecteplase versus alteplase in acute ischemic stroke patients with large vessel occlusion
نویسندگان
چکیده
منابع مشابه
A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
BACKGROUND Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. METHODS In this phase 2B trial, we randomly assigned 75 patients to receive alteplase (0.9 mg per kilogram of body weight) or tenecteplase (0.1 mg per kilogram or 0.25 mg per kilogram) less ...
متن کاملSafety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients.
BACKGROUND AND PURPOSE We investigated whether early initiation of tirofiban, a glycoprotein IIb/IIIa antagonist, is safe, can reduce the risk of reocclusion, and improve outcomes in acute ischemic stroke patients after alteplase. METHODS Forty-one patients received alteplase followed by intravenous tirofiban infusion for at least 24 hours. The incidence of symptomatic intracranial hemorrhage...
متن کاملSafety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke
Background: Thrombolytic therapy is the only approved treatment for acute cerebral ischemia. The hemorrhagic transformation is the greatest complication of this treatment, which may occur after recanalization of occluded artery. The aim of this study was to determine factors associated with clinical improvement and worsening in patients with acute ischemic stroke treated with intravenous th...
متن کاملOccurrence of intracranial large vessel occlusion in consecutive, non-referred patients with acute ischemic stroke
Background: The relative frequency of acute intracranial large vessel occlusion (LVO) in patients with acute ischemic stroke (AIS) who could be candidate for intra-arterial treatment (IAT) is not well known. In this study, we determined clinical variables associated with LVO and the proportion of patients with LVO among patients presenting with AIS within 6 h of symptom onset. Methods: Data of ...
متن کاملCoagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke.
BACKGROUND AND PURPOSE We compared the fibrinolytic activity of tenecteplase and alteplase in patients with acute ischemic stroke, and explored the association between hypofibrinogenaemia and intracerebral hemorrhage. METHODS Venous blood samples from a subgroup of participants in the Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST) study were obtained at pretreatment,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutic Advances in Neurological Disorders
سال: 2021
ISSN: 1756-2864,1756-2864
DOI: 10.1177/1756286420986727